Skip to main content
SpringerLink
Log in

Lamifiban

A Viewpoint by Robert A. Harrington

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  2. Harrington RA. Platelet inhibition in cardiovascular disease management: aspirin and beyond. J Thromb Thrombol 1998; 5: S37–41

    Article  Google Scholar 

  3. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischaemic heart disease. Circulation. In press

  4. Steiner B, Hofer U, Wittke B, et al. Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A. Eur Heart J 1998; 19: 598

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA

    Robert A. Harrington

Authors
  1. Robert A. Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrington, R.A. Lamifiban. Drugs 57, 222 (1999). https://doi.org/10.2165/00003495-199957020-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957020-00010

Keywords

Search

Navigation